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1 Institute of Virology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität
zu Berlin, and Berlin Institute of Health, Berlin, Germany, 2 PEPperPRINT GmbH, R&D unit, Heidelberg, Germany,
3 Department of Infectious Diseases and Respiratory Medicine, Charité—Universitätsmedizin Berlin, Corporate Member of
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The WHO declared the COVID-19 outbreak a public health emergency of international
concern. The causative agent of this acute respiratory disease is a newly emerged
coronavirus, named SARS-CoV-2, which originated in China in late 2019. Exposure to
SARS−CoV−2 leads to multifaceted disease outcomes from asymptomatic infection to
severe pneumonia, acute respiratory distress and potentially death. Understanding the
host immune response is crucial for the development of interventional strategies. Humoral
responses play an important role in defending viral infections and are therefore of particular
interest. With the aim to resolve SARS-CoV-2-specific humoral immune responses at the
epitope level, we screened clinically well-characterized sera from COVID-19 patients with
mild and severe disease outcome using high-density peptide microarrays covering the
entire proteome of SARS-CoV-2. Moreover, we determined the longevity of epitope-
specific antibody responses in a longitudinal approach. Here we present IgG and IgA-
specific epitope signatures from COVID-19 patients, which may serve as discriminating
prognostic or predictive markers for disease outcome and/or could be relevant for
intervention strategies.
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COVID-19 is an acute respiratory disease caused by SARS-CoV-2, which emerged in China in
December 2019 (1, 2). Due to the rapid global spread and increase in number of cases, the World
Health Organization (WHO) declared COVID-19 a pandemic in March 2020. As of November 13,
2020, more than 51 million confirmed COVID-19 cases have been reported from 220 countries,
areas, or territories with over 1.2 million fatalities (3). The course of disease ranges from
asymptomatic to milder symptoms such as fever and cough, to severe outcomes with
pneumonia, respiratory distress, and potentially death (4–6). Most vulnerable for severity areorg March 2021 | Volume 12 | Article 6291851
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obesity. Enormous efforts are ongoing, aiming to develop
efficacious and timely drugs, and 48 vaccines are currently in
clinical evaluation and the first already in use (7, 8). The rapid
availability of sequence data enabled the development of
molecular diagnostic tests for the detection of SARS-CoV-2 (9,
10) which are key for patient management and the
implementation of measures to combat the pandemic.
Intensive research is ongoing to develop and validate specific
and sensitive serological assays (11–23), mainly focusing on IgG,
IgM, and/or IgA antibody response against single target proteins.
However, these assays reflect only a small fraction of the humoral
response. Furthermore, possible antibody cross-reactivity due to
sequence similarities between SARS-CoV-2 and the four
endemic human coronaviruses, and especially, an even higher
degree of similarity to SARS-CoV is a challenge to overcome (14,
18, 19). In-depth understanding of SARS-CoV-2 specific
antibody responses is not only crucial for the development of
diagnostics but also for epidemiological studies and intervention
strategies, such as vaccine development and monitoring. To date,
proteome-wide analyses of humoral responses elicited in
COVID-19 patients are still limited (24–27). Microarray-based
technologies are ideally suited for profiling proteome-
wideantibody responses in a high-throughput context.
In this study, we present a proteome-wide analysis on epitope
level SARS-CoV-2 specific antibody responses using peptide
microarrays. The high peptide-to-peptide overlap of our SARS-
CoV-2 proteome array allows a high-resolution epitope analysis
giving a detailed picture of antibody binding patterns,
contributing to better characterization of SARS-CoV-2-specific
humoral immune responses.MATERIAL AND METHODS
Serum Samples/Study Population
For longitudinal analysis and comparison of the humoral
response, sera of PCR-confirmed COVID-19 patients with
mild (n=9) and severe (n=7) course of disease were used.
Patients with mild courses are part of a well-characterized
cohort (28, 29). Patients with severe courses, defined by the
need of admission to an intensive care unit, are included in the
Pa-COVID-19 study at Charité - Universitätsmedizin Berlin
(30). Serum samples (n=7) for SARS-CoV-2 naive control
group were collected from healthy volunteers with no contact
to COVID-19 patients and no reported COVID-19 associated
symptoms. Ethical approval was granted by the local Ethics
Committee of the Charité - Universitätsmedizin Berlin (EA2/
066/20, EA1/068/20) and the Ethics Committee at the Medical
Faculty of the Ludwig Maximilians Universität Munich (vote 20-
225 KB) in accordance with the guidelines of the Declaration
of Helsinki.
ELISA
For the detection of SARS-CoV-2 specific antibodies to the spike
(S) protein and to the Nucleocapsid (NCP) protein, we used anti-Frontiers in Immunology | www.frontiersin.org 2SARS-CoV-2 S1 IgG, anti-SARS-CoV-2 S1 IgA and anti−SARS-
CoV-2 NCP ELISAs according to manufacturer’s instructions
(EUROIMMUN Medizinische Labordiagnostika AG, https://
www.euroimmun.com). Serum samples were tested at a 1:101
dilution using the fully EUROIMMUN Analyzer I. For all
analyses, optical density (OD) was detected at 450 nm and
ratios were calculated by dividing the observed OD by that of
the calibrator included in the kit. The OD ratio can be utilized as
a relative measure for the concentration of antibodies in serum.
For IgG and IgA, an OD ratio of 0.8-1.09 was considered
borderline, and values above 1.1 to be reactive.
Plaque Reduction Neutralization Test
To test neutralizing activity of SARS-CoV-2 antibodies of ELISA
reactive sera plaque reduction neutralization test (PRNT) were
done as previously described (29, 31). Briefly, Vero E6 cells were
seeded in 24-well-plates and incubated overnight. Heat-
inactivated sera were diluted in OptiPro and mixed 1:1 with
100 plaque forming units of SARS-CoV-2 (strain MT270112.01).
Each well was incubated with the serum-virus solutions for 1
hour at 37°C. Then the supernatants were discarded, cells were
washed with PBS, and overlaid with 1.2% Avicel solution in
DMEM. After 3 days at 37°C, cells were fixed and inactivated by
utilizing a 6% formaldehyde/PBS solution and stained with
crystal violet. Serum dilutions with a plaque reduction of 50%
(PRNT50) are referred to as titers.
Peptide Microarrays
The PEPperCHIP® SARS-CoV-2 Proteome Microarray
(PEPperPRINT GmbH, Germany) covers the entire proteome
of SARS-COV-2 isolate Wuhan-Hu-1 (GenBank ID:
MN908947.3). The protein sequences of ORF1a/b, Spike
protein, ORF3a, Envelope protein, Membrane glycoprotein,
ORF6, ORF7a, ORF8, Nucleocapsid phosphoprotein and
ORF10 were translated into 15 amino acid peptides with a
peptide-peptide overlap of 13 amino acids. This results in
4,883 individual peptides, which were printed in duplicates.
The PEPperCHIP® SARS-CoV-2 Proteome Microarray further
contains influenza hemagglutinin and polio control peptides
(108 spots each control peptide).
The peptide microarrays were incubated for 15 minutes in
phosphate buffered saline supplemented with 0.05% Tween 20
(PBS-T, pH 7.4) and blocked for 30 minutes with Rockland
Blocking Buffer (RL) (Rockland Immunochemicals) at room
temperature. Prior to immunoassay, patient sera were heat-
inactivated at 56°C for 30 minutes. Microarrays were incubated
at serum dilutions of 1:100 in 10% RL/PBS-T overnight at 4°C
with orbital shaking. After washing (3 times with PBS-T for 1
minute), peptide binding was detected with isotype-specific
secondary goat ant i -human IgG (Fc) DyLight680
(ThermoFisher Scientific) and goat anti-human IgA (alpha
chain) DyLight800 (Rockland Immunochemicals) antibodies at
a final concentration of 0.1 µg/ml and 1 µg/ml, respectively (in
10% RL/PBS-T for 45 minutes at room temperature). Subsequent
washing (3 times with PBS-T for 1 minute) was followed by
dipping the microarrays in 1mM TRIS pH 7.4 and drying with
pressurized air. Images were acquired with a LI-COR OdysseyMarch 2021 | Volume 12 | Article 629185
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resolution 21 µm). The resulting 32-bit gray-scale TIFF files
were converted into 16-bit gray-scale TIFF files using ImageJ
(Fiji) software and subsequently analyzed with PepSlide®
Analyzer (SICASYS Software GmbH). The PEPperPRINT
software algorithm calculated median foreground intensities
(background-corrected intensities) of each spot and spot-to-
spot deviations of spot duplicates. We tolerated a maximum
spot-to-spot deviation of 40%, otherwise, the corresponding
intensity value was zeroed. In addition, the microarray scans
were reassessed with respect to artifacts by visual inspection, and
erroneous values were corrected manually.
Statistical Analysis
The statistical analysis for this study was performed in the R
language (version 4.0.2). The detailed statistical workflow is
given in Figure 1B. The background-corrected median
intensities (raw values) of IgG and IgA response values
(generated as described in section Peptide Microarrays) were
used for analysis. A positive response was defined as ≥ 500 FU
(fluorescence intensity units) and signals below 500 FU were set
to zero, accordingly. Peptides with (i) 0 FU in all individuals and
(ii) with 0 FU in all infected individuals were removed from
further analysis. For the longitudinal analysis of antibody
responses, the applied filtering criteria resulted in 1905
remaining peptides for IgG and 1775 peptides for IgA. For the
comparison of patients with mild versus severe symptoms, the
applied filtering criteria resulted in 2054 remaining peptides
for IgG and 1830 peptides for IgA. The remaining filtered
peptide raw values for IgG and IgA isotypes were normalized
using variance stabilizing normalization (VSN) (32). The
Linear Models for Microarray Analysis (LIMMA-version
3.44.3) package was used to identify the peptide reactivity for
each study in IgG and IgA isotypes by fitting peptide-wise linear
models to the normalized data. In the LIMMA package, we
used the lmFit and empirical Bayes (eBayes) functions to find
the statistically significant peptides between the group
comparisons. False discovery rate (FDR) was controlled
at the p-value < 0.1 using the Benjamini Hochberg
procedure. The respective raw data (background-corrected
median intensities) and statistically processed data are
summarized in Supplementary Tables S1–S4.RESULTS
SARS-CoV-2 Peptidome-Wide Antibody
Profiling
In order to examine SARS-CoV-2-specific humoral responses on
epitope level, we screened peptide microarrays covering the
entire SARS-CoV-2 proteome with sera from COVID-19
patients and healthy controls (Figure 1A). We investigated
antibody profiles (i) longitudinally, in COVID-19 patients
(n=7) with mild disease symptoms (28, 29) and (ii) in patients
with mild (n=9) versus severe (n=7) COVID-19 disease. We
applied a dual isotype read-out, analyzing IgG and IgA specificFrontiers in Immunology | www.frontiersin.org 3antibody responses against SARS-CoV-2. Subjects (n=7) with
neither anamnestic COVID-19 episode nor detectable
SARSCoV-2 S1-antibodies served as healthy control group.
The subsequent statistical analysis of the obtained peptide
microarray data was performed according to the workflow
shown in Figure 1B . The data are summarized in
Supplementary Tables S1–S4.
Longitudinal Monitoring of Epitope-
Specific Antibody Responses Across the
SARS-CoV-2 Proteome
We examined the antibody reactivity in sera of COVID-19
patients collected at different time points post symptom onset
(p.o.) (Figure 1A). All patients have underwent a mild COVID-
19 disease course and recovered (28, 29). Sera from SARS-CoV-2
naive subjects were used as controls. Overall, the breadth of
responses was heterogeneous across COVID-19 patients for both
IgG and IgA (Figure 2, Supplementary Figure S1). For IgG,
epitope-specific antibody responses were already detectable early
after symptom onset (week 1) and increased in most instances
towards later time points in both magnitude and breadth. For
some epitopes, antibody responses waned over time (Figure 2,
Supplementary Figure S2). Early IgA-specific epitope responses
were rather weak but peaked 3 weeks p.o. before declining until
around week 10 for most of the epitopes (Figure 2,
Supplementary Figures S1, S3). Some background reactivity
in the SARS-CoV-2-naive control group was detected,
presumably due to cross-reactivity of antibodies against the
four endemic human coronaviruses. The heterogeneity of anti-
SARS-CoV-2 humoral responses was also shown by ELISA
measuring antibodies against the S1 subunit of Spike protein
and Nucleocapsid Phosphoprotein and neutralizing antibody
titers measured by plaque reduction neutralization test (PRNT)
(Table 1).
To determine significant SARS-CoV-2-specific epitopes, VSN
normalized values from the COVID-19 disease groups were
compared to corresponding responses from the SARS-CoV-2-
naive group using the LIMMA algorithm (Figure 1B,
Supplementary Tables S1 and S2, Figure 3). For IgG
responses, our analysis identified nine peptides reaching
statistical significance when COVID-19 patients at week 9/10
p.o. were compared to SARS-CoV-2-negative subjects (Figure
3A). Interestingly, antibody reactivity against one epitope
(E6662-R6676) was significant across the entire time span of
analysis (Figures 3B, C). Sequence alignment identified E6662-
R6676 as a non-structural protein (NSP) 15-derived peptide. The
recognition pattern for the other peptides was rather
heterogeneous at the earlier time points, resulting in statistical
significance only at week 9/10 p.o. Most of the peptides could be
assigned to proteins located in the ORF1a/b polyprotein (Figure
3B). The comparison of IgA-specific epitope responses in sera of
SARS-CoV-2-infected patients with control sera resulted in
no peptides reaching statistical significance. However,
when considering peptides solely based on log fold changes
(LFC > 4) between naive and infected cohorts, several epitopes
were identified (Supplementary Figure S4B). Amongst others,March 2021 | Volume 12 | Article 629185
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FIGURE 1 | Study overview and statistical analysis workflow: SARS-CoV-2 proteome-wide IgG and IgA epitope mapping. (A) The proteome of SARS-CoV-2 was
translated in 15-mer overlapping peptides with a peptide-to-peptide overlap of 13 amino acids. The resulting 4,883 individual peptides were printed in duplicates on
the microarray. Sera from confirmed COVID-19 patients and SARS-CoV-2-naive individuals were incubated on PEPperCHIP® SARS-CoV-2 Proteome Microarrays.
Serum antibody binding was visualized using respective fluorescently labeled secondary antibodies (anti-human IgG and anti-human IgA). Image acquisition and data
quantification resulted in epitope-specific antibody profiles for SARS-CoV-2. (B) The statistical analysis was performed in the R language (version 4.0.2). Data
quantification resulted in background-corrected median fluorescence intensity values (raw data) which were subjected to the following pre-processing steps:
(i) signals below 500 FU (fluorescence units) were set as zero, (ii) peptides with 0 FU in all individuals were removed and (iii) peptides with 0 FU in all infected
individuals were removed. For the longitudinal analysis, the applied pre-processing steps resulted in 1905 remaining peptides for IgG and 1775 peptides for IgA. For
the comparison of patients with mild versus severe symptoms, the applied pre-processing steps resulted in 2054 remaining peptides for IgG and 1830 peptides for
IgA. Next, the remaining filtered raw values were normalized using variance stabilizing normalization (VSN) followed by statistical analysis based on the LIMMA
algorithm. The false discovery rate (FDR) was controlled at a p-value < 0.1 using Benjamini Hochberg procedure.Frontiers in Immunology | www.frontiersin.org March 2021 | Volume 12 | Article 6291854
Schwarz et al. SARS-CoV-2 Proteome-Wide Epitope Analysisthe analysis revealed epitopes C649-D663 (Spike protein), A143-
C157 (ORF3a protein) and E5466-E5480 (NSP13), which were
shared between IgG (Figure 3B) and IgA responses
(Supplementary Figure S4B) at later disease stages.
All identified epitopes with a log fold change > 4 between
naive and infected cohorts are summarized in Supplementary
Figure S4. Our analysis revealed 38 IgG-specific epitopes
(excluding the nine peptides described in Figure 3) and 16
epitopes specific for IgA together with 10 epitopes that are
shared between both antibody isotypes (Supplementary Figure
S4). For IgG, antibody responses against six epitopes
(Supplementary Figure S4A) were continuously detectableFrontiers in Immunology | www.frontiersin.org 5throughout the time period of analysis as observed for E6662-
R6676 (Figures 3B, C). Two of the six epitopes (L4534-Y4548
(NSP12), E2940-Y2954 (NSP4)) were also recognized by
IgA week 3 and 10 p.o. For most of the peptides identified for
IgG, log fold changes > 4 were observed at week 10 p.o.
(Supplementary Figure S4A), with one peptide shared
between IgG and IgA (E2550-L2564 (NSP3)). Measuring IgA-
specific antibody responses over time revealed that the majority
of identified epitopes peaked week 3 p.o. and waned thereafter
(Supplementary Figures S2, S4B). In contrast to IgG, no IgA-
specific epitope was detected at early disease stages (within week
1 p.o.).FIGURE 2 | Longitudinal IgG and IgA epitope-specific antibody profiles in COVID-19 patients. For visualization purposes, the heat-maps show the epitope
recognition profile for a selected number of peptides (IgG and IgA antibody profiles across the entire proteome are presented in Supplementary Figure S1). The
selection of peptides was performed applying the following pre-processing criteria: (i) signals below 500 FU (fluorescence intensity units) were set to zero and (ii)
peptides with 0 FU in all individuals were removed. This resulted in 2226 remaining peptides for IgG and 2046 remaining peptides for IgA. The heat-maps show the
IgG and IgA raw fluorescence intensities for the selected, reduced number of peptides detected for each individual in the corresponding cohort. Sera taken week 1,
week 3, and week 10 p.o. from COVID-19 patients with a mild disease course (n=7) and sera taken from SARS-CoV-2-naive individuals were incubated on whole-
proteome peptide microarrays. The data for COVID-19 patients for all time points are shown in the following order: patient #2, #4, #3, #8, #7, #1, #10. Serum
antibody binding was visualized with fluorescently-labeled secondary antibodies detecting IgG and IgA. The peptide specificities underlying Figure 2 are provided in
Supplementary Table S5. NSP, non-structural protein; E, Envelope protein; M, Membrane protein; N, Nucleocapsid Phosphoprotein.March 2021 | Volume 12 | Article 629185
TABLE 1 | IgG and IgA serum levels and PRNT50 titers against SARS-CoV-2 of COVID-19 patients and non COVID-19 patients.














.46 3.04 1.65 >640# 1.25 0.94 1.41 160
.56 3.58 0.83 320# 3.91 3.82 0.91 80
.26 5.77 0.62 >640# 2.38 2.10 0.53 80
.77 2.35 0.43 160# 1.24 0.82 0.41 80
.17 >11 6.06 >1280# 7.79 >14 5.85 >640
.96 5.94 0.43 >320# 5.23 3.59 1.26 320
.28 1.12 0.33 >40# 0.87 2.31 1.09 160
.93 9.75 5.30 >40#
.84 1.32 >320#
.96 >13 4.24 320
.1 >12 5.03 >640
.14 13.28 6.58 80
.49 >9 >9 320
.01 >13 4.74 640
.26 12.15 6.38 640




















































patient 1 mild 0.18 0.34 0.22 1
patient 2 mild 0.22 0.33 0.06 1
patient 3 mild 0.24 0.87 0.10 3
patient 4 mild 0.17 0.17 0.18 0
patient 7 mild 0.18 0.18 0.30 10
patient 8 mild 0.17 0.15 0.05 3
patient 10 mild 0.26 0.98 0.06 0
patient 14 mild 7








C01 control 0.16 0.21
C02 control 0.47 1.07
C03 control 0.22 0.5
C04 control 0.24 0.37
C05 control 0.35 0.25
C06 control 0.4 0.98
C07 control 0.3 0.42
OD, optical density *control sera were obtained from healthy volunteers with no reported symptoms.
#Data were previously published by Wölfel et al. (29); §PRNT values are given as reciprocal titers.
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FIGURE 3 | Epitope-specific antibody response in COVID-19 patients over time. (A) The LIMMA package was used to determine significant differences in epitope
recognition comparing SARS-CoV-2-naive individuals and SARS-CoV-2-infected individuals at different time points p.o. Volcano plots are shown for the comparison
between SARS-CoV-2-naive and SARS-CoV-2-infected individuals week 1, week 3, and week 10 p.o., respectively. Volcano plots are depicted with the Log fold
change of the intensity of each peptide (x-axis) versus the negative log10 FDR adjusted p-value (y-axis). The Log fold change of a certain peptide is the mean
difference in value between the respective groups that are compared. An FDR below < 0.1 was considered as statistically significant. Each dot in the volcano plot
represents one peptide. The purple highlighted data points indicate peptides identified for IgG that are significantly recognized in SARS-CoV-2-infected individuals.
The grey dots represent peptides that did not reach statistical significance. The results of the statistical analysis are provided in Supplementary Table S1.
(B) Individual IgG antibody responses to the nine peptides significantly identified in COVID-19 patients. The reactivity patterns in all cohorts (naive control group;
COVID-19 patients week 1, week 3 and week 10 p.o.) are shown as heat-maps using VSN normalized values. The data for COVID-19 patients for all time points are
shown in the following order: patient #2, #4, #3, #8, #7, #1, #10. Peptides underlined indicate overlapping peptides. (C) Individual IgG antibody responses to the
nine peptides significantly identified in COVID-19 patients as violin plots. p.o., post symptom onset; w, week.Frontiers in Immunology | www.frontiersin.org March 2021 | Volume 12 | Article 6291857
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antibody responses in COVID-19 patients demonstrated the
presence of IgG antibodies, which were already detectable quite
early during the course of illness until the late convalescent phase
in the majority of patients (IgG antibodies recognizing the
peptide E6662-R6676 (NSP15)). Apart from that, increasing
IgG antibody reactivities were identified over time, with the
most robust responses in the convalescent phase such as IgG
antibodies recognizing the peptide E5466-E5480 (NSP13).
Finally, investigating the dynamics of epitope-specific IgA
responses showed a clear peak in the early convalescent phase
(week 3 p.o.) before declining for most of the epitopes.
SARS-CoV-2-Specific Epitope Signature in
Patients With Mild And Severe COVID-19
Disease
To identify antibody reactive epitopes associated with mild and/
or severe COVID-19 disease, sera from COVID-19 patients
taken week 2-3 p.o. and SARS-CoV-2-naive controls were
probed on whole-proteome SARS-CoV-2 peptide microarrays
(Figure 1A). Overall, the breadth of IgG and IgA antibody
responses across the proteome varied among individual subjects
with more heterogeneous responses in mild cases. However, the
range of epitope heterogeneity and response intensities was highly
variable within one patient group. (Supplementary Figure S5).
High variances from undetectable to very strong responses
towards Spike S1 and Nucleocapsid proteins were also observed
by ELISA, particularly in individuals with mild COVID-19.
Furthermore, this heterogeneity was reflected in the neutralizing
antibody titers, which ranged from >40 to >1280 (Table 1).
Because the array screening was performed on linear and not on
conformational peptide arrays, the experimental setting did not
allow a direct comparison of array data with ELISA and PRNT
data. Spike S1 and Nucleocapsid ELISAs and PRNT measure
immune responses to presumably conformational epitopes,
whereas the array experiments detect linear epitopes only.
Further data analysis (Figure 1B, Supplementary Tables S3,
S4) revealed significant differential epitopes for mild and severe
disease outcomes (Figure 4). Compared to mild disease, severe
COVID-19 is associated with a higher number of significant,
linear B cell epitopes for both IgG and IgA responses (Figures
4A, B). Notably, numerous severe-disease epitopes can be
assigned to NSP3 and 12 (Figure 4B). IgG antibody reactivity
against peptide P1622-H1636 (NSP3) was most powerful
(adjusted p-value 4.7E-07) to discriminate severe from mild
COVID-19 disease, followed by the NSP12-derived peptide
N4542-D4556 (p-value 4.3E-04). Although less significant, a
NSP3-derived IgA epitope (Y1906-Y1920) was most
comprehensive in severe COVID-19 cases (adjusted p-value
1.4E-02). Moreover, our approach identified three IgG and IgA
shared epitopes recognized in sera from patients with a serious
disease course (Figure 4B) with the ORF3a-derived peptide
Y141-D155 (p-value IgG 6.9E-04; p-value IgA 3.9E-02)
representing the best discriminative shared epitope.
For mild disease, only a few peptides reached statistical
significance when compared to the severe cohort (Figures 4A, B).Frontiers in Immunology | www.frontiersin.org 8When the detected antibody responses against these mild-disease
peptides were compared to the naive control group, there was no
significant discrimination (adjusted p-value ≥ 0.1).
Taken together, analyzing epitope-specific antibody reactivity
in sera from patients with mild and critical COVID-19 clinical
presentation identified SARS-CoV-2 specific epitopes which may
have the potential to discriminate disease outcome.DISCUSSION
A detailed understanding of the immune response following
infection with SARS-CoV-2 is invaluable for disease control,
identification of new diagnostic markers and development and
monitoring of potent antiviral drugs and vaccines. With the aim
to study the SARS-CoV-2 specific humoral immune responses
and to identify (potential) discriminative markers for disease
outcome, we analyzed both the longevity of COVID-19
associated antibodies and the epitope signatures in patients
with mild and severe disease. Using peptide microarrays
covering the entire proteome of SARS-CoV-2 as overlapping
peptides, global IgG and IgA profiles were obtained in patients
with mild and severe COVID-19 disease and unexposed
healthy controls.
Several studies are available analyzing the time course of
antibody responses towards SARS-CoV-2 using cross-sectional
and/or longitudinal patient samples (14, 19, 23, 24, 33–42). Most
of these studies focus on responses against Nucleocapsid, Spike
protein, and subunits of Spike protein, respectively. There is
growing evidence that IgM and IgA responses decline rapidly
while IgG responses are more stable, potentially waning at later
time points and at a slower rate, which is in good agreement with
our data. Monitoring longitudinal epitope-specific antibody
responses across the SARS-CoV-2 proteome revealed a short-
lived IgA and a more stable IgG response. Heterogeneity of
individual antibody responses, as observed in our study, is
consistent with previous studies (43) with COVID-19 patients
not mounting a detectable antibody response to highly variable
titers of SARS-CoV-2 specific antibodies.
To our knowledge, there is one study investigating
overlapping B cell epitopes across the entire proteome of
SARS-CoV-2 in a longitudinal set up (24). By using the same
peptide microarray as in the present study, Dahlke et al.
demonstrated a strong IgA response early p.o. (week 1) for
mild COVID-19 disease, which declined towards week 4. A
similar trend was also observed for IgG, however with less
reactive peptides as compared to IgA responses (24). This is in
contrast to our data, as we detected rather weak early (week 1)
IgA-specific responses by both peptide microarray analysis and
ELISA. Moreover, IgG responses increased towards week 3 p.o.
with a slight decrease towards week 10. The discrepancy between
the two studies might be due to the number of samples studied,
as the study by Dahlke and co-workers (24) analyzed a very small
number of patients (with mild COVID-19 disease represented by
sequential samples from one patient).March 2021 | Volume 12 | Article 629185
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FIGURE 4 | Linear B cell epitopes associated with mild and severe COVID-19 disease. (A) The LIMMA package was used to determine significant differences in
epitope recognition comparing mild and severe COVID-19 disease. Volcano plots are shown for the comparison between mild and severe COVID-19 disease for IgG
and IgA. Volcano plots are depicted with the Log fold change of the intensity of each peptide (x-axis) versus the negative log10 FDR adjusted p-value (y-axis). The
Log fold change of a certain peptide is the mean difference in value between the respective groups that are compared. An FDR of < 0.1 was considered as
statistically significant. Each dot in the volcano plot represents one peptide. The purple (IgG) and orange (IgA) highlighted data points indicate epitopes that are
significantly recognized. For IgG, the right-side purple dots correspond to significant severe disease-specific peptides and the left-side purple dots correspond to
significant mild disease-specific peptides. For IgA, the right-side orange dots correspond to significant severe-specific peptides and the left-side orange dot
correspond to one significant mild-specific peptide. The grey dots represent peptides that did not reach statistical significance. (B) Individual antibody responses to
peptides significantly associated with mild and disease severity. The reactivity patterns in all cohorts (naive control group, COVID-19 patients with mild and severe
disease) and for both isotypes are shown as heat-maps using VSN normalized values. Underlined peptides indicate overlapping peptides. * indicates no significant
discrimination from the naive control group. Adjusted p-value for the comparison between mild and severe disease cohort and Log fold change (LogFC) between
mild and severe disease cohort was determined by LIMMA analysis. The results of the statistical analysis are provided in Supplementary Tables S3 and S4.Frontiers in Immunology | www.frontiersin.org March 2021 | Volume 12 | Article 6291859
Schwarz et al. SARS-CoV-2 Proteome-Wide Epitope AnalysisWe identified the NSP15-derived peptide E6662-R6676 as a
potential serological marker of acute, early and late convalescent
(up to day 60-70 p.o.) of mild COVID-19 disease (Figure 3).
NSP15 (endoribonuclease) has been discussed as a drug target
(44, 45) and recently, amongst other SARS-CoV-2 proteins, was
identified as an interferon antagonist functioning in immune
suppression (46). There is only limited data available on SARS-
CoV-2 NSP15 as a target for humoral responses (25, 26). In a
study using a protein array covering ~60% of the SARS-CoV-2
proteome, no significant anti-NSP15 responses in COVID-19
convalescent sera were detected (25). However, protein arrays
address conformational rather than linear epitopes. A NSP15-
derived epitope was identified by peptide microarray screening,
however with no sequence overlap to either E6662-R6676 or to
the second identified NSP15-derived peptide S6740-F6754
(Figure 3B). The absence of sequence overlaps also applies to
the other identified peptides reaching statistical significance in
our analysis. This might be due to the contrasting amino acid
offsets used for peptide microarray synthesis (26). Wang and
colleagues screened 15-mer peptides with an offset of 10 amino
acids (26), while the PEPperCHIP® SARS-CoV-2 Proteome
Microarray comprises 15-mers with an offset of 2 amino acids.
Besides, the number of patients was small in both studies (≤ 10)
and patients were of different ethnic origin, which might affect
epitope recognition.
Recently, antibody responses against ORF8 and ORF3b were
described as serological markers of early and late SARS-CoV-2
infection (35) using the luciferase immunoprecipitation system
(LIPS) assay. In our analysis, antibody responses against ORF8
did not reach statistical significance when COVID-19 patients
were compared to healthy controls. When considering peptides
solely based on log fold changes (LFC >4), few ORF8 protein-
derived peptides were identified (Supplementary Figure S4) for
both IgG and IgA. However, in contrast to the study by Hachim
and colleagues using full-length antigen-fusion proteins, we did
not observe a maintained antibody response targeting ORF8 at
the epitope level in any patients. Additional data on antibody
responses towards ORF8 are limited (24–27), especially
thoseexamining longitudinal samples. For ORF3b, further data
on the antigenicity with respect to eliciting humoral responses
have not been published until now. ORF3b uses an alternative
start codon (ATG) located within the genomic region of ORF3a
(47, 48) and whole-proteome studies to date have not yet
considered ORF3b (24–27), which also applies for our study.
Hence, additional research is necessary to shed more light on
anti-ORF3b (as well as anti-ORF8) associated antibody
responses. In the case of the NSP15-derived epitope E6662-
R6676 discovered in the present study, its suitability as a
serological marker for early and late COVID-19 disease needs
to be validated in future studies with larger patient cohorts,
including longitudinal samples from COVID-19 patients with
different disease severities.
For the late convalescent phase of infection, we moreover
identified NSP3 (papain-like protease), 12 (RNA-dependent
RNA Polymerase), 13 (Helicase), Spike and ORF3a-derived
peptides. NSP3, 12, and 13 are also under investigation as drugFrontiers in Immunology | www.frontiersin.org 10targets for COVID-19 (49–52), whereas Spike protein is known
to mediate host cell entry (53) and ORF3a protein is described as
modulating the host immune response to virus infection, hence
having a role in pathogenesis (54, 55). Antibody reactivity
against ORF3a has already been detected in SARS-CoV-
positive patients in 2003/2004 (56) and Akerström et al.
determined that the N-terminal ectodomain of ORF3a induces
neutralizing antibodies (57). Of note, the Spike protein-derived
epitope C649-D663 discovered in our study is located in the S1
domain, adjacent to the S1/S2 cleavage site [AA681-685, (53)].
C649-D663 is recognized by both IgG (Figure 3B) and IgA
(Supplementary Figure S4B). Interestingly, the sequence
partially overlaps with immunodominant epitopes discovered
by Yi et al. [S1-65; EHVNNSYECDIPIGAGICAS; (58)] and
Farrera-Soler et al. [AA655-672; HVNNSYECDIPIGAGICA;
(59)] for convalescent COVID-19. The latter study provided
evidence that serum with antibodies recognizing the Spike-
derived epitope AA655-672 inhibits cleavage mediated by furin
(59). Whether antibodies targeting the epitope C649-D663 are
also capable of inhibiting furin-mediated proteolysis of Spike
remains to be determined. Other reports investigating linear B
cell epitopes on SARS-CoV-2 Spike discovered further
immunodominant linear epitopes (24, 26, 27, 60–62). Overall,
differences in recognized peptide sequences might be explained
by differences among (i) applied screening technologies, (ii)
peptide lengths (ranging from 15-25 amino acids) and peptide-
peptide overlaps (5-13 amino acids) and (iii) patient cohorts and
study design (e.g., time points of serum collection).
The clinical picture of COVID-19 is multifaceted with
classifications from asymptomatic, mild, moderate to severe
disease (4–6). The identification of correlates of COVID-19
disease severity is crucial for clinical management and
intervention strategies. In this respect, hematological and
immunological markers are evaluated as prognostic biomarkers
(63–65). Aiming to uncover epitopes associated with different
disease outcomes, we compared the epitope signatures of
patients with mild and severe COVID-19 disease in the early
convalescent phase (week 3 p.o.). In general, there are reports
demonstrating that antibody titers are higher in patients with
severe disease (23, 33, 37, 40, 66, 67), however others show the
contrary (68). These studies focused on antibody responses
elicited by Spike and/or Nucleocapsid protein. To gain a more
comprehensive picture, we evaluated antibody responses across
the entire SARS-CoV-2 peptidome.
Our analysis revealed several linear B cell epitopes, which
were significantly associated with severe COVID-19 disease
(Figures 4A, B). The majority of these epitopes is derived
from proteins encoded in the Orf1a/b locus locus, with
sequences originating from NSP3 and NSP12 as being the
most common. In fact, the most significant detected peptides
recognized by IgG represent the NSP3-derived peptide P1622-
H1636 (p-value 4.7E-07) and the NSP12-derived peptide N4542-
D4556 (p-value 4.3E-04); for IgA, the peptide Y1906-Y1920
originating from NSP3 (p-value 1.4E-02). Interestingly, the best
discriminative peptide for severe COVID-19 recognized by both
antibody isotypes can be assigned to the ORF3a Protein (Y141-March 2021 | Volume 12 | Article 629185
Schwarz et al. SARS-CoV-2 Proteome-Wide Epitope AnalysisD155; p-value IgG 6.9E-04; p-value IgA 3.9E-02). For mildly ill
patients, only a minority of peptides reached statistical
significance when compared to severely ill patients. So far, only
one study evaluated the association of epitope-specific antibody
responses with disease severity (60). Two Spike protein- and one
Nucleocapsid protein-derived peptides demonstrated a
significantly higher magnitude of antibody responses in severe
as compared to mild cases at median 23 days p.o. Of note, higher
IgG responses in severe cases were not detected earlier during the
course of the disease (60). With regard to a possible use as
discriminating biomarkers for disease severity, the detection in
an early stage of disease would be crucial. In this context, it would
be important to validate our potential discriminative markers
with sera from early disease stages. Overall, the clinical
significance of identified epitopes needs to be verified.
Our study identified only few linear epitopes derived from
SARS-CoV-2 Spike protein. This is in contrast to the ELISA data,
showing strong responses to Spike protein particularly in
patients with severe COVID-19. However, these results did not
translate into high immunoreactivity towards Spike-derived
microarray peptides. These findings suggest that the immune
response to Spike is predominantly directed against
conformational epitopes. Structure analyses characterizing the
binding modes of neutralizing SARS-CoV-2 antibodies to SARS-
CoV-2 Spike protein and the RBD revealed discontinuous and
strictly conformational epitopes (69–73), which cannot be
addressed by linear peptide microarray screening.
Given the high similarity of the SARS-CoV-2 proteome to
SARS-CoV (47) especially in the NSPs, the cross-reactivity of
described epitopes needs further investigations (including
samples from recovered SARS-CoV patients). Sequence
alignments demonstrated few amino acid substitutions between
SARS-CoV and SARS-CoV-2 for some epitopes. Whether or not
these changes have an influence on antibody recognition has to
be further explored. The Spike-derived peptide C131-Y145
(CEFQFCNDPFLGVYY) identified under the most significant
matches for severe COVID-19, harbors the highest number of
amino acid substitutions (SARS-CoV sequence: AA128-142;
CNFELCDNPFFAVSK) suggesting a SARS-CoV-2 specific
antibody response. In this context, identified ORF8-derived
epitopes might be of great interest as the amino acid sequence
identity between SARS-CoV-2 and SARS-CoV is only 40% (47).
Another aspect which needs further evaluation is possible
immune cross-reactivity with antibodies elicited after infection
(s) with seasonal human coronaviruses (74). We included
control samples taken from healthy volunteers, however
patient samples with confirmed cases of hCoV-229E, hCoV-
NL63, hCoV-OC43 and hCoV-HKU-1, should be used in follow-
up studies to get a more detailed picture of possible cross-
reactivities. Finally, our peptide microarray study is based on
the proteome sequence of the virus isolate Wuhan-Hu-1
(GenBank ID: MN908947.3), and so does not yet incorporate
sequence information from other SARS-CoV-2 isolates.
Genome-wide analyses of different SARS-CoV-2 isolates
revealed sequence variations across the genome and thus also
substitutions at the amino acid level (75, 76). It remains to beFrontiers in Immunology | www.frontiersin.org 11determined whether the discovered epitopes in our study are
conserved across multiple SARS-CoV-2 isolates.
Altogether, our study identified linear B cell epitopes
potentially applicable for early and/or late COVID-19 disease
detection and as biomarkers able to discriminate severe from
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Supplementary Figure 1 | Longitudinal IgG and IgA epitope-specific antibody
profiles in COVID-19 patients across the entire SARS-CoV-2 proteome. The heat-
map shows raw fluorescence intensities for each peptide detected for each
individual in the corresponding cohort. Intensity values below 100 FU were set to
zero. Sera taken week 1, week 3, and week 10 p.o. from COVID-19 patients with a
mild disease course (n=7) and sera taken from SARS-CoV-2-naive individuals were
incubated on whole-proteome peptide microarrays. The data for COVID-19
patients for all time points are shown in the following order: patient #2, #4, #3, #8,
#7, #1, #10. Serum antibody binding was visualized with fluorescently-labeled
secondary antibodies detecting IgG and IgA. The peptide specificities underlying
Figure S1 are provided in Supplementary Tables S1 and S2. E = Envelope
protein; M = Membrane protein; N = Nucleocapsid Phosphoprotein.
Supplementary Figure 2 | Longitudinal IgG epitope-specific antibody profiles in
COVID-19 patients presented as percentage responders. For visualization
purposes, the longitudinal epitope recognition profile is shown for a selected
number of peptides as percentage responders. Peptide selection was performed
applying the following pre-processing criteria: (i) signals below 500 FU (fluorescence
intensity units) were set to zero, and (ii) peptides with 0 FU in all individuals were
removed. This resulted in 2226 remaining peptides. Groups of responders were
defined as follows: 0%, 1-20%, 21-40%, 41-60%, 61-80%, 81-100% and color-
coded accordingly. The peptide underlying specificities Figure S2 are provided in
Supplementary Table S5.
Supplementary Figure 3 | Longitudinal IgA epitope-specific antibody profiles in
COVID-19 patients presented as percentage responders. For visualization
purposes, the longitudinal epitope recognition profile is shown for a selected
number of peptides as percentage responders. Peptide selection was performed
applying the following pre-processing criteria: (i) signals below 500 FU (fluorescence
intensity units) were set to zero and (ii) peptides with 0 FU in all individuals were
removed. This resulted in 2046 remaining peptides. Groups of responders were
defined as follows: 0%, 1-20%, 21-40%, 41-60%, 61-80%, 81-100% and color-Frontiers in Immunology | www.frontiersin.org 12coded accordingly. The peptide underlying specificities Figure S3 are provided in
Supplementary Table S5.
Supplementary Figure 4 | Longitudinal IgG and IgA epitope-specific antibody
reactivity patterns against selected peptides in COVID-19 patients. Individual IgG (A)
and IgA (B) antibody responses to selected epitopes based on Log fold change > 4
between SARS-CoV-2-negative subjects (n=7) and SARS-CoV-2-infected individuals
(n=7) week 1, week 3 and week 10 p.o., respectively. The heat-map shows VSN
normalized intensity values for each peptide detected for each individual in the
corresponding cohort. The data for COVID-19 patients for all time points are shown in
the following order: patient #2, #4, #3, #8, #7, #1, #10. The black dots in the last
column indicate the time point (week 1, 3, 10) at which the Log fold change between
infected and naïve cohort for a given peptide is > 4. Connected dots indicate
consecutive time points at which this was observed. LogFC, Log fold change; p.o.,
post symptom onset.
Supplementary Figure 5 | IgG and IgA antibody responses in COVID-19
patients with mild and severe disease outcome across the SARS-CoV-2 proteome.
The heat-map shows raw fluorescence intensities for each peptide detected for
each individual in the corresponding cohort. Intensity values below 100 FU were set
to zero. Sera taken week 2-3 p.o. from COVID-19 patients with a mild disease
course (n=9) and COVID-19 patients with a severe disease course (n=7) were
incubated on whole-proteome peptide microarrays. Sera from SARS-CoV-2-naive
individuals were used as control. Serum antibody binding was visualized with
fluorescently-labeled secondary antibodies detecting IgG and IgA. The peptide
specificities underlying Figure S5 are provided in Supplementary Tables S3 and
S4. E = Envelope protein; M = Membrane protein; N = Nucleocapsid
Phosphoprotein.Supplementary Table 1 | Peptide microarray data – Longitudinal analysis - IgG.
Supplementary Table 2 | Peptide microarray data – Longitudinal analysis - IgA.
Supplementary Table 3 | Peptide microarray data – Severe vs mild - IgG.
Supplementary Table 4 | Peptide microarray data – Severe vs mild - IgA.
Supplementary Table 5 | Data for Figure 2_S2_S3 – Longitudinal analysis.REFERENCES
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